Clinical Research Directory
Browse clinical research sites, groups, and studies.
FAPI PET for Lung Fibrosis
Sponsor: University of California, Los Angeles
Summary
This is a prospective exploratory biodistribution study in patients with interstitial lung disease (ILD). The purpose of this research study is to determine where and to which degree the FAPI tracer (68Ga-FAPI-46) accumulates in normal and fibrotic lung tissues of patients with interstitial lung disease. The study will include patients with interstitial lung disease who have or will initiate a new ILD medication OR will undergo tissue biopsy or surgery of the lung. The study will include 30 patients, the upper limit for PET imaging studies conducted under the Radioactive Drug Research Committee (RDRC) purview. Participants will be injected with up to 7 mCi of 68-GaFAPi and will undergo one PET/CT scan and one High Resolution CT of the lungs. The study is sponsored by Ahmanson Translational Theranostic Division at UCLA.
Official title: PET Study of 68Ga-FAPi-46 in Patients With Interstitial Lung Disease: an Exploratory Biodistribution Study With Histopathology Validation.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2021-11-16
Completion Date
2026-12
Last Updated
2025-07-03
Healthy Volunteers
No
Conditions
Interventions
68Ga-FAPi-46
Radiopharmaceutical will be administered via IV
Computed Tomography
As part of PET/CT scan
Positron Emission Tomography
As part of PET/CT scan
High Resolution Computed Tomography
Will be conducted immediately after FAPI PET/CT
Locations (1)
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States